e-learning
resources
Munich 2014
Wednesday, 10.09.2014
Ceremony for the ERS Idiopathic Pulmonary Fibrosis Research Award 2014 - Hot Topic: "Understanding and treating idiopathic pulmonary fibrosis (IPF) in the 21st century"
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Recent clinical treatment trials in IPF that focus on pirfenidone and nintedanib
L. Richeldi (Southampton, United Kingdom)
Source:
International Congress 2014 – Ceremony for the ERS Idiopathic Pulmonary Fibrosis Research Award 2014 - Hot Topic: "Understanding and treating idiopathic pulmonary fibrosis (IPF) in the 21st century"
Session:
Ceremony for the ERS Idiopathic Pulmonary Fibrosis Research Award 2014 - Hot Topic: "Understanding and treating idiopathic pulmonary fibrosis (IPF) in the 21st century"
Session type:
Hot topics
Number:
4803
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. Richeldi (Southampton, United Kingdom). Recent clinical treatment trials in IPF that focus on pirfenidone and nintedanib. International Congress 2014 – Ceremony for the ERS Idiopathic Pulmonary Fibrosis Research Award 2014 - Hot Topic: "Understanding and treating idiopathic pulmonary fibrosis (IPF) in the 21st century"
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on Basic translational and clinical research – building a career in paediatric pulmonology- experiences from clinicians in lower middle income countries
ERS/EAACI statement on severe exacerbations in asthma in adults: facts, priorities and key research questions
Definition and history of sarcoidosis
Related content which might interest you:
Tolerability and efficacy of Pirfenidone and Nintedanib for patients with IPF in real world clinical practice
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Recent clinical trials in idiopathic pulmonary fibrosis and the BUILD-1 study
Source: Eur Respir Rev 2008; 17: 116-122
Year: 2008
COPD treatment from pathophysiology to clinical trials
Source: ERS Live 2007
Year: 2007
Efficacy and tolerability of nintedanib switched from pirfenidone for IPF patients
Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia
Year: 2019
Effect of nintedanib on blood biomarkers in patients with IPF in the INMARK trial
Source: International Congress 2019 – Biomarkers and beyond in idiopathic interstitial pneumonia
Year: 2019
Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial
Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia
Year: 2020
Emerging concepts in outcome assessment for COPD clinical trials
Source: Annual Congress 2007 - PG13 - Outcome measures of clinical trials for new drugs for respiratory disease
Year: 2007
Efficacy and safety of combined use of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Clinical effectiveness of MDI-HFA-Modulite budesonide in the treatment of asthma – meta-analysis of randomised controlled trials
Source: Eur Respir J 2006; 28: Suppl. 50, 315s
Year: 2006
Therapeutic effects of nintedanib are not influenced by emphysema in the INPULSIS trials
Source: Eur Respir J, 53 (4) 1801655; 10.1183/13993003.01655-2018
Year: 2019
Concomitant medications and efficacy of nintedanib in patients with IPF
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Placebo effects in pharmaceutical clinical trials in bronchiectasis: an EMBARC study
Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria
Year: 2020
Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
Source: Eur Respir Rev 2015; 24: 58-64
Year: 2015
Current clinical trials
Source: ERS Research Seminar 2017 – Immunotherapy: a new standard of care in thoracic malignancies?
Year: 2017
Real-life comparison between pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis
Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia
Year: 2021
Heterogeneity of treatment response in bronchiectasis clinical trials
Source: Virtual Congress 2020 – New investigations of bronchiectasis and non-tuberculous mycobacteria
Year: 2020
Efficacy and safety of pirfenidone in patients with IPF. A single center real-life experience.
Source: International Congress 2017 – Idiopathic pulmonary fibrosis: from the bench to the bedside
Year: 2017
Erdosteine is effective as a treatment for acute exacerbation of COPD: a systematic review of clinical trials
Source: International Congress 2017 – COPD management
Year: 2017
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept